Pieris’ Publications
Pulmonary Delivery of PRS-400 Anti-Jagged-1 Anticalin® Proteins Reduce Inflammation-Driven Goblet Cell Metaplasia and Mucus Hypersecretion in Vivo
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Preclinical profile of PRS-220, a novel inhaled inhibitor of CTGF/CCN2, in clinical development for Idiopathic Pulmonary Fibrosis
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Development of PRS-400, an inhaled Jagged-1-specific Anticalin® protein for the treatment of muco-obstructive lung diseases. ERS 2022.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
PRS-220, a novel inhalable therapeutic intervention for IPF, targeting CTGF directly in the lung. ATS 2022.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
The Anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1–dependent manner. AACR 2022.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. ERS 2022.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. AACR 2021.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS- 344/S095012, a 4-1BB/PD-L1 bispecific compound for tumor-localized activation of the immune system. AACR 2021.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies.ESMO 2020.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. SITC 2019.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Bruns IB, Fitzgerald MF, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Jiang F, Lickliter J, Close DR5 Phase 1 evaluation of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Rα Abstract: OA5336
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Bruns IB, Fitzgerald MF, Mensing G, Tsung M, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Olsson M, Ghobadi C, Walsh O, McLendon K, Farinola N, Hatchuel L, Close DR. Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Bruns IB, Fitzgerald MF, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Jiang F, Lickliter J, Close DR. First-in-human data for the inhaled IL-4Rα antagonist AZD1402/PRS-060 reveals a promising clinical profile for the treatment of asthma.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Birgit Bossenmaier, Corinna Schlosser, Rachida-Siham Bel Aiba, Eva-Maria Hansbauer, Thomas Jaquin, Christian Barthels, Janet Peper, Markus Zettl, Benjamin Weiche, Thibaut Angevin, Michelle Yegres, Reno Winter, Stefan Grüner, Christine Rothe, Shane A. Olwill. Costimulatory T-cell engagement by PRS-342, a GPC3/4-1BB bispecific molecule, leads to activation of T cells and tumor growth inhibition in a HCC humanized mouse model.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Marina Pavlidou, Janet Peper, Lucia Pattarini, Christian Barthels, Eva-Maria Hansbauer, Rachida Bel Aiba, Milan Blanusa, Alix Scholer-Dahirel, Maximilien Grandclaudon, Céline Grand, Jamila Elhmouzi-Younes, Matthieu Rivière, VéroniqueBlanc, Christine Rothe, Shane Olwill. Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Katerina Pardali, Fanyi Jiang, Mary Fitzgerald, Gabriele Matschiner, David Keeling. AZD1402/PRS-060, an inhaled Anticalin IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Marlon J. Hinner, Rachida-Siham Bel Aiba, Corinna Schlosser, Thomas Jaquin, Andrea Allersdorfer, Sven Berger, Alexander Wiedenmann, Gabriele Matschiner, Julia Schüler, Ulrich Moebius, Christine Rothe, Shane A. Olwill Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and tumor-localized CD8(+) T cell expansion in a humanized mouse model
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Marlon J. Hinner, Rachida-Siham Bel Aiba, Thomas Jaquin, Sven Berger, Manuela Dürr, Corinna Schlosser, Andrea Allersdorfer, Christine Rothe, Louis A. Matis, Shane A. Olwill Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
G. Matschiner, S. Huang, S. Constant, B. Rattenstetter, H. Gille, A.M. Hohlbaum, B.H. Koller, D. Keeling & M. Fitzgerald (2018) The Discovery and Development of AZD1402/PRS-060 a Potent and Selective Blocker of the IL-4 Receptor alpha
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Lutz Renders, Frank Dellanna, František Švára, Jitka Řehořová, Ondřej Viklický, Ming Wen, Matthias Braunisch, Karoline Meurer, Anne Maschek, Goran Martić, Kayti Aviano, Louis Matis, Ingmar Bruns. A Phase 2a Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations of the hepcidin antagonist prs-080 over 4 weeks in anemic chronic kidney disease patients undergoing hemodialysis.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Lutz Renders, Ming Wen, Frank Dellanna, Sven Heinrichs, Klemens Budde, Christian Rosenberger, Christiane Erley,Birgit Bader, Claudia Sommerer, Schaier, Matthias, Werner Feuerer, Edgar Fenzl, Rachel van Swelm, Dorine Swinkels, Klaus Kutz, Louis Matis, Ulrich Moebius, Safety, tolerability, and pharmacodynamics of the hepcidin antagonist PRS-080#022-DP after single administration – a phase Ib study in anemic chronic kidney disease patients undergoing hemodialysis
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Lutz Renders, Ming Wen, Frank Dellanna, Heinrichs, Sven, Klemens Budde, Christian Rosenberger, Christiane Erley, Birgit Bader, Claudia Sommerer, Schaier, Matthias, Werner Feuerer, Edgar Fenzl, Rachel van Swelm, Dorine Swinkels, Klaus Kutz, Louis Matis, Ulrich Moebius (2017) A phase Ib study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease patients undergoing hemodialysis
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Hendrik Gille, Martin Hülsmeyer, Stefan Trentmann, Gabriele Matschiner, Hans Jürgen Christian, Todd Meyer, Ali Amirkhosravi, Laurent P. Audoly, Andreas M. Hohlbaum, Arne Skerra (2015) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Marlon J. Hinner, Rachida-Siham Bel Aiba, Alexander Wiedenmann, Corinna Schlosser, Andrea Allersdorfer, Gabriele Matschiner, Christine Rothe, Ulrich Moebius, Shane A. Olwill (CRI 2015 Poster Presentation) Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-HER2 protein based on Anticalin® technology
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA (2014) In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Gebauer M, Schiefner A, Matschiner G, Skerra A. (2013) Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schönfeld, D., Matschiner, G., Chatwel,l L., Trentmann, S., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P.M., Schlehuber, S., Hohlbaum, A.M., Skerra, A. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. PNAS 19;106(20):8198-203.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika Stern, Hendrik Gille, Laurent P. Audoly, Max E. Scheulen (2013) First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Coby M. M. Laarakkers, Erwin T. Wiegerinck, Siem Klaver, Maria Kolodziejczyk, Hendrik Gille, Andreas M. Hohlbaum, Harold Tjalsma, Dorine W. Swinkels (2013) Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. (2013) A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther. Sep 3.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Martz L. (2009) Designer Lipocalins. SciBX 2(28) 8-9. Kim, H.J., Eichinger, A., Skerra A. (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc. 131(10):3565-76.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Skerra, A. (2008) Alternative binding proteins: Anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 275(11):2677-83
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Breustedt, D.A., Schonfeld, D.L., Skerra, A. (2006) Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta. 1764(2), 161-173.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Nasreen, A., Vogt, M., Kim, H.J., Eichinger, A., Skerra, A. (2006) Solubility engineering and crystallization of human apolipoprotein D. Protein Sci. 15(1), 190-199.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Vopel, S., Muhlbach, H., Skerra, A. (2005) Rational engineering of a fluorescein-binding anticalin for improved ligand affinity. Biol Chem. 386(11), 1097-1104.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S. & Skerra, A. (2005) Anticalins in Drug Development. BioDrugs, 19(5), 279-288.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S. & Skerra, A. (2005) Anticalins as an alternative to antibody technology. Expert Opin. Biol. Ther. 5(11), 1453-1462.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S. & Skerra, A. (2005) Lipocalins in drug discovery: from natural ligand-binding proteins to ‘anticalins’. Drug Discov. Today 10, 23-33.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Breustedt, D. A., Korndörfer, I. P., Redl, B. & Skerra, A. (2005) The 1.8-Å; crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J. Biol. Chem. 280, 484-493.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Nygren, P.-Å;. & Skerra, A. (2004) Binding proteins from alternative scaffolds. J. Immunol. Methods 290, 3-28.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Vogt, M. & Skerra, A. (2004) Construction of an artificial receptor protein (“Anticalin”) based on the human apolipoprotein D. ChemBioChem 5, 191-199.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Liu, G., Mills, J. L., Hess, T. A., Kim, S., Skalicky, J. J., Sukumaran, D. K., Kupce, E., Skerra, A. & Szyperski, T. (2003) Resonance assignments for the 21 kDa engineered fluorescein-binding lipocalin FluA. J. Biomol. NMR 27, 187-188.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Korndörfer, I. P., Beste, G. & Skerra, A. (2003) Crystallographic analysis of an “anticalin” with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins: Struct. Funct. Genet. 52, 121-129.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Korndörfer, I. P., Schlehuber, S. & Skerra, A. (2003) Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol. Biol. 330, 385-396.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Götz, M., Hess, S., Beste, G., Skerra, A. & Michel-Beyerle, M.E. (2002) Ultrafast electron transfer in the complex between fluorescein and a cognate engineered lipocalin protein, a so-called anticalin. Biochemistry 41, 4156-4164.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S., & Skerra, A. (2002) Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant – a so-called ‘anticalin’ – using a molecular random approach. Biophys. Chem. 96, 213-228.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Skerra, A. (2001) ‘Anticalins’: a new class of engineered ligand-binding proteins with antibody-like properties. Rev. Mol. Biotechnol. 74, 257-275.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S., & Skerra, A. (2001) Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem. 382, 1335-1342.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Schlehuber, S., Beste, G. & Skerra, A. (2000) A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 297, 1105-1120.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Skerra, A. (2000) Lipocalins as a scaffold. Biochim. Biophys. Acta 1482, 337-350.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Skerra, A. (2000) Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13, 167-187.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More
Beste, G., Schmidt, F. S., Stibora, T. & Skerra, A. (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. USA 96, 1898-1903.
Palvella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations(Microcystic LMs). QTORIN rapamycin…
Read More